Advances in Animal Models and Cutting-Edge Research in Alternatives: Proceedings of the Third International Conference on 3Rs Research and Progress, Vishakhapatnam, 2022.

3Rs NAMs Three Rs animal models animal-free drug discovery microphysiological system new approach methodologies organ-on-a-chip organoid organs-on-chips replacement spheroid tissue microenvironment

Journal

Alternatives to laboratory animals : ATLA
ISSN: 0261-1929
Titre abrégé: Altern Lab Anim
Pays: England
ID NLM: 8110074

Informations de publication

Date de publication:
Jul 2023
Historique:
medline: 24 7 2023
pubmed: 7 6 2023
entrez: 7 6 2023
Statut: ppublish

Résumé

Animal experimentation has been integral to drug discovery and development and safety assessment for many years, since it provides insights into the mechanisms of drug efficacy and toxicity (e.g. pharmacology, pharmacokinetics and pharmacodynamics). However, due to species differences in physiology, metabolism and sensitivity to drugs, the animal models can often fail to replicate the effects of drugs and chemicals in human patients, workers and consumers. Researchers across the globe are increasingly applying the Three Rs principles by employing innovative methods in research and testing. The Three Rs concept focuses on: the

Identifiants

pubmed: 37282515
doi: 10.1177/02611929231180428
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-288

Auteurs

Nikita Narayan Naik (NN)

Oncoseek Bio Pvt Ltd, Hyderabad, India.

Bharadwaja Vadloori (B)

Oncoseek Bio Pvt Ltd, Hyderabad, India.

Suresh Poosala (S)

Oncoseek Bio Pvt Ltd, Hyderabad, India.

Pratima Srivastava (P)

Biology Discovery and Services Division, Aragen Life Science, Hyderabad, India.

Sandra Coecke (S)

European Commission Joint Research Centre, Ispra, Italy.

Adrian Smith (A)

Norecopa c/o Norwegian Veterinary Institute, Oslo, Norway.

Aysha Akhtar (A)

Center for Contemporary Sciences, Gaithersburg, MD, USA.

Clive Roper (C)

Roper Toxicology Consulting Limited, Edinburgh, UK.

Sridhar Radhakrishnan (S)

Research Diets Inc, New Brunswick, NJ, USA.

Balaji Bhyravbhatla (B)

HyLasCo Bio-Technology (India) Pvt Ltd, Hyderabad, India.

Madhujit Damle (M)

Molecular Devices, Mumbai, India.

Venkat Koushik Pulla (VK)

Merck Life Sciences, Mumbai, India.

Johannes Hackethal (J)

THT Biomaterials GmbH, Vienna, Austria.

Reyk Horland (R)

TissUse GmbH, Berlin, Germany.

Albert P Li (AP)

Discovery Life Sciences, Columbia, MD, USA.

Falguni Pati (F)

Department of Biomedical Engineering, IIT Hyderabad, Hyderabad, India.

Manu Smriti Singh (MS)

Department of Biotechnology and Center of Excellence for Nanosensors and Nanomedicines, Bennett University, Noida, India.

Paola Occhetta (P)

BiomimX Srl, Milan, Italy.

Rohit Bisht (R)

Department of Science-Regulatory Toxicology, People for the Ethical Treatment of Animals (PETA), Delhi, India.

Prajakta Dandekar (P)

Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India.

Krishna Bhagavatula (K)

The Jackson Laboratory, Bar Harbor, ME, USA.

Dasja Pajkrt (D)

Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Michael Johnson (M)

Visikol, Hampton, NJ, USA.

Tilo Weber (T)

Animal Welfare Academy of the German Animal Welfare Federation, Neubiberg, Germany.

John Huang (J)

TheWell Bioscience, North Brunswick, NJ, USA.

Lisiena Hysenaj (L)

Parvus Therapeutics Inc., South San Francisco, CA, USA.

Banerjee Mallar (B)

Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India.
BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India.

Bhat Ramray (B)

Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India.
BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India.

Santosh Dixit (S)

Persistent Systems, Pune, India.

Shreekanth Joshi (S)

Persistent Systems, Pune, India.

Mandar Kulkarni (M)

VCR Park, Vishakhapatnam, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH